Orchid Pharma share news, announcements and annual reports
NSE: ORCHPHARMABSE: 524372Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹893.40.
30 Oct: open ₹893.45, high ₹893.45, low ₹830.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,009 Cr919th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 88,12456.8% delivered
Orchid Pharma share news and announcements
856 announcements, routine notices left out, newest first. Page 5 of 18.
Feb 2023
1 Feb · Management
Jan 2023
9 Jan
Dec 2022
24 Dec · Rating
15 Dec · Analysts
12 Dec · Corporate action
6 Dec · Extra Ordinary Meeting
2 Dec · Extra Ordinary Meeting
1 Dec · Board meeting
Nov 2022
28 Nov · Related Party Transaction
28 Nov · Board meeting
Oct 2022
Sep 2022
28 Sep · General updates
26 Sep · General updates
23 Sep · General updates
23 Sep · General updates
Aug 2022
Jul 2022
16 Jul · Communication to shareholders as per Reg 30
16 Jul · Communication to shareholders as per Reg 30
Jun 2022
30 Jun · Communication to shareholders as per Reg 30
24 Jun · Communication to shareholders as per Reg 30
20 Jun · Communication to shareholders as per Reg 30
18 Jun · Communication to shareholders as per Reg 30
15 Jun · Legal
Exchange has sought clarification from Orchid Pharma Limited with respect to announcement dated 14-Jun-2022 informing about appointment of Internal Auditor.On the basis of aforesaid announcement, the Company is required to provide/clarify the following:Change in directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), Auditor and Compliance Officer: 1. Brief profile (in case of appointment) The response of the company is awaited.14 Jun · Communication to shareholders as per Reg 30
May 2022
26 May · Legal
Exchange has sought clarification from Orchid Pharma Limited for the quarter ended 31-Mar-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is awaited.26 May · Related Party Transaction
12 May · Results
Apr 2022
26 Apr · Communication to shareholders as per Reg 30
7 Apr · Communication to shareholders as per Reg 30